What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cardiology
Nazzareno Galiè mainly focuses on Pulmonary hypertension, Internal medicine, Surgery, Placebo and Cardiology.
His Pulmonary hypertension research incorporates elements of Respiratory disease, Bosentan, Sitaxentan, Endothelin receptor antagonist and Randomized controlled trial.
His study brings together the fields of Endocrinology and Internal medicine.
His Surgery study integrates concerns from other disciplines, such as Tadalafil and Confidence interval.
His research integrates issues of Anesthesia, Treprostinil and Macitentan in his study of Placebo.
The Cardiology study combines topics in areas such as Survival rate and COPD.
His most cited work include:
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). (3529 citations)
- Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) (2467 citations)
- Bosentan therapy for pulmonary arterial hypertension. (2301 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Cardiology, Pulmonary hypertension, Surgery and Hemodynamics.
His Placebo research extends to the thematically linked field of Internal medicine.
His Placebo research incorporates themes from Adverse effect, Selexipag, Hazard ratio, Riociguat and Macitentan.
His Cardiology study combines topics from a wide range of disciplines, such as Sildenafil and Blood pressure.
His studies in Pulmonary hypertension integrate themes in fields like Clinical trial, Endothelin receptor antagonist, Intensive care medicine, Disease and Pulmonary artery.
His Surgery research integrates issues from Gastroenterology, Tadalafil, Tolerability and Combination therapy.
He most often published in these fields:
- Internal medicine (64.37%)
- Cardiology (48.05%)
- Pulmonary hypertension (40.69%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.37%)
- Cardiology (48.05%)
- Pulmonary hypertension (40.69%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Cardiology, Pulmonary hypertension, Intensive care medicine and In patient.
His Hazard ratio, Randomized controlled trial, Macitentan, Adverse effect and Clinical endpoint investigations are all subjects of Internal medicine research.
His Randomized controlled trial research is multidisciplinary, incorporating perspectives in Odds ratio, Heart disease and Selexipag.
Within one scientific family, Nazzareno Galiè focuses on topics pertaining to Confidence interval under Cardiology, and may sometimes address concerns connected to Stent and Valve replacement.
His study of Chronic thromboembolic pulmonary hypertension is a part of Pulmonary hypertension.
In his work, Hypertension risk is strongly intertwined with Etiology, which is a subfield of Intensive care medicine.
Between 2018 and 2021, his most popular works were:
- Risk stratification and medical therapy of pulmonary arterial hypertension (199 citations)
- An overview of the 6th World Symposium on Pulmonary Hypertension (115 citations)
- Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. (43 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cardiology
Nazzareno Galiè mostly deals with Internal medicine, Cardiology, Pulmonary hypertension, Hazard ratio and Selexipag.
His study in Cardiology is interdisciplinary in nature, drawing from both Survival analysis, Outpatient clinic and Prospective cohort study.
He studies Eisenmenger syndrome which is a part of Pulmonary hypertension.
Nazzareno Galiè has included themes like Transcatheter aortic, Stent, Surgery and Stent thrombosis in his Hazard ratio study.
His Selexipag research incorporates elements of Randomized controlled trial, Etiology and Intensive care medicine.
The study incorporates disciplines such as Treprostinil and Endothelin receptor antagonist in addition to Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
